Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
---|
11/16/2000 | CA2374237A1 Compositions and methods for identifying antigens which elicit an immune response |
11/16/2000 | CA2373851A1 Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells |
11/16/2000 | CA2373443A1 Steroid compounds with a c17-alkyl side chain and an aromatic a-ring for use in therapy |
11/16/2000 | CA2373348A1 Opioid antagonists containing compositions for enhancing analgesic potency of tramadol and attenuating its adverse side effects |
11/16/2000 | CA2373193A1 Process for preparing (1r,2s,4r) -(-)-2-[(2'- {n,n-dimethylamino} -ethoxy)] -2-[phenyl] -1,7,7-tri- [methyl] -bicyclo [2.2.1] heptane and pharmaceutically acceptable acid additionsalts thereof |
11/16/2000 | CA2373173A1 Aromatic amides |
11/16/2000 | CA2373079A1 Substituted benzolactam compounds |
11/16/2000 | CA2373068A1 Spray drying of thrombin inhibitors |
11/16/2000 | CA2372815A1 Extracellular matrix and adhesion-associated proteins |
11/16/2000 | CA2372738A1 Low-dose il-1.beta.-induced photoreceptor cell rescue without retinal dysplasia |
11/16/2000 | CA2372704A1 Use of phthalazine derivatives |
11/16/2000 | CA2372496A1 Aryl amidines, compositions containing such compounds and methods of use |
11/16/2000 | CA2372492A1 Cyclic amidines useful as nmda nr2b antagonists |
11/16/2000 | CA2371902A1 Novel nucleic acids and proteins with interferon-beta activity |
11/16/2000 | CA2371472A1 Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands |
11/16/2000 | CA2371279A1 Recombinant vaccine against botulinum neurotoxin |
11/16/2000 | CA2371219A1 Methods for screening gaba-modulatory compounds for specified pharmacological activities |
11/16/2000 | CA2369333A1 Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use |
11/16/2000 | CA2369323A1 Heterosubstituted pyridine derivatives as pde 4 inhibitors |
11/15/2000 | EP1052259A1 Novel optically active aminopentane derivative |
11/15/2000 | EP1052255A1 Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgetics. |
11/15/2000 | EP1052245A2 High purity (1R, 2S, 4R)-(-)-2-[(2'-(N,N-dimethylamino)-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof, process for the preparation of these compounds and medicaments containing them |
11/15/2000 | EP1052243A2 Process for preparing (1R, 2S, 4R)-(-)-2-[(2'-(N,N-dimethylamino)-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof |
11/15/2000 | EP1051995A2 5HT1 receptor agonists and a cox-2 inhibitor or NSAID for the treatment of migraine |
11/15/2000 | EP1051994A2 5HT1 receptor agonists and a cox-2 inhibitor for the treatment of migraine |
11/15/2000 | EP1051993A2 5HT1 receptor agonists and either a cox-2 inhibitor or NSAID for the treatment of migraine |
11/15/2000 | EP1051980A2 Dopamine transporter imaging agents |
11/15/2000 | EP1051975A1 Dry mix formulation for bisphosphonic acids |
11/15/2000 | EP1051972A1 Nitric oxide donor composition and method for treatment of anal disorders |
11/15/2000 | EP1051971A1 Patch and method for transdermal delivery of bupropion base |
11/15/2000 | EP1051521A2 Method of screening therapeutic agents |
11/15/2000 | EP1051429A1 Ldl related protein and uses thereof |
11/15/2000 | EP1051416A1 1,4-diazacycloheptane derivatives for the treatment of neurological disorders |
11/15/2000 | EP1051415A1 Benzamide derivatives as vasopressin antagonists |
11/15/2000 | EP1051395A1 Hydroxamic and carboxylic acid derivatives |
11/15/2000 | EP1051393A1 New derivatives of sulfonic, phosphonic and phosphinic aminoalkane acids, their production and their use as medicaments |
11/15/2000 | EP1051392A1 Adamantanecarboximidamide derivatives and their use as nmda antagonists |
11/15/2000 | EP1051195A1 Identification of agents that protect against inflammatory injury to neurons |
11/15/2000 | EP1051182A1 Methods of decreasing or preventing pain using spicamycin or derivatives thereof |
11/15/2000 | EP1051176A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS |
11/15/2000 | EP1051173A1 Derivatives of 1,3,4-oxadiazolone |
11/15/2000 | EP1051170A1 Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration |
11/15/2000 | EP1051167A1 Pharmaceutical uses of optically pure (-) -bupropion |
11/15/2000 | EP1051166A1 Pharmaceutical uses of optically pure (+) -bupropion |
11/15/2000 | EP1051165A2 Mitochondria protecting agents for treating mitochondria associated diseases |
11/15/2000 | EP1051164A1 Pharmacological uses of pure (+) -bupropion |
11/15/2000 | EP1051163A2 Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-)-bupropion |
11/15/2000 | EP1051161A1 Method for treating alzheimer's disease |
11/15/2000 | EP0717635B1 Methods for regulating gastrointestinal motility |
11/15/2000 | CN1273581A Method and reagents for N-alkylating ureides |
11/15/2000 | CN1273579A Anthranilic acid analogs |
11/15/2000 | CN1273534A Method for treating neurological deficits |
11/15/2000 | CN1058495C Polycyclic systems compound and derivatives thereof as neurotransmitter release enhancers useful in the treatment of cognitive disordes and medicine containing them and its use |
11/14/2000 | US6147230 Amino acid dysiherbaine |
11/14/2000 | US6147224 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors |
11/14/2000 | US6147223 Lactacystin analogs |
11/14/2000 | US6147190 Protein associated with activating cell propagation; for the treatment of a nervous system disorders; for diagnosis and treatment of tumors; antitumor agents |
11/14/2000 | US6147188 Irreversible cathepsin or calpain inhibitors |
11/14/2000 | US6147122 Oil in water emulsion used for injection with antimicrobial growth agent; prevents growth of escherchia, candida, pseudomonas, and staphylococcus |
11/14/2000 | US6147110 Heterocyclic compounds |
11/14/2000 | US6147102 Topical aqueous gel suitable for relieving sympathetically maintained peripheral neuropathic pain syndrome |
11/14/2000 | US6147096 Substituted pyrrolobenzimidazoles for treating inflammatory diseases |
11/14/2000 | US6147087 Use of 1,2-Bridged 1,4-dihydropyridines as medicaments |
11/14/2000 | US6147085 Aminoalkyl substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives |
11/14/2000 | US6147080 Inhibitors of p38 |
11/14/2000 | US6147079 N-(4-acetyl-1-piperazinyl)-4-fluorobenzamide hydrate |
11/14/2000 | US6147075 Analgesics; psychological disorders |
11/14/2000 | US6147073 Substituted tetralymethylen-Oxindoles analogues as tyrosine kinase inhibitors |
11/14/2000 | US6147072 Administering antidepressant and serotonin reuptake inhibitor |
11/14/2000 | US6147066 Use of antimineralocorticoid compounds against drug withdrawal syndrome |
11/14/2000 | US6147063 Therapeutic substituted guanidines |
11/14/2000 | US6147061 Antiarthritic agents; anticancer agents; oral diseases |
11/14/2000 | US6146876 22025, a novel human cyclic nucleotide phosphodiesterase |
11/14/2000 | US6146845 Polynucleotides encoding a sialoadhesin family member-2 (SAF-2) |
11/14/2000 | US6146835 Nucleotide sequence; for drug screening of novel analgesics; for recombinant production of receptor |
11/14/2000 | US6146636 Substance P antagonists comprising rosaceae plant extracts |
11/14/2000 | US6146624 Human ubiquitin-conjugating enzymes |
11/14/2000 | CA2308826A1 Combination therapy for the treatment of migraine |
11/14/2000 | CA2308824A1 Combination therapy for the treatment of migraine |
11/14/2000 | CA2308323A1 5ht1 receptor agonists and either a cox-2 inhibitor or nsaid for the treatment of migraine |
11/14/2000 | CA2188933C Apolipoprotein e polymorphism and treatment of alzheimer's disease |
11/14/2000 | CA2105912C Nadh and nadph as drugs for treating alzheimer's disease |
11/14/2000 | CA2080221C An improved process for the preparation of substituted indolone derivatives |
11/14/2000 | CA2050284C Pcp receptor ligands and the use thereof |
11/14/2000 | CA1341139C Tetrahydropyridine oxime cholinergic agents and method of treatment |
11/12/2000 | CA2721484A1 Dopamine transporter imaging agents |
11/10/2000 | CA2307958A1 Patch and method for transdermal delivery of bupropion base |
11/09/2000 | WO2000067029A1 Method for identifying an individual at risk for irreversible neurodamages, comprising the steps of determining quantitatively the concentration of pepsinogen i (pgi) and vitamin b12 |
11/09/2000 | WO2000067016A1 Methods for the identification of compounds for the treatment of alzheimer's disease |
11/09/2000 | WO2000066737A1 VARIANTS OF TRAF2 WHICH ACT AS AN INHIBITOR OF TNF-ALPHA (TNF α) SIGNALING PATHWAY |
11/09/2000 | WO2000066736A1 Growth factor homolog zvegf4 |
11/09/2000 | WO2000066735A2 Human ion channel proteins |
11/09/2000 | WO2000066732A2 Laminin 8 and methods for its use |
11/09/2000 | WO2000066730A2 Laminin 2 and methods for its use |
11/09/2000 | WO2000066713A2 Materials and methods relating to neuronal development |
11/09/2000 | WO2000066630A1 DNA ENCODING SNORF36a AND SNORF36b RECEPTORS |
11/09/2000 | WO2000066617A1 Methods for the treatment of neuronal atrophy-associated dementia |
11/09/2000 | WO2000066614A1 3α-HYDROXY-3β METHOXYMETHYL-21-HETEROCYCLE SUBSTITUTED STEROIDS WITH ANESTHETIC ACTIVITY |
11/09/2000 | WO2000066611A1 Steroid derivatives |
11/09/2000 | WO2000066587A2 Polyamines and their use in therapy |